↓ Skip to main content

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

Overview of attention for article published in British Journal of Cancer, August 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
71 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer
Published in
British Journal of Cancer, August 2014
DOI 10.1038/bjc.2014.463
Pubmed ID
Authors

K L Mahon, W Qu, J Devaney, C Paul, L Castillo, R J Wykes, M D Chatfield, M J Boyer, M R Stockler, G Marx, H Gurney, G Mallesara, P L Molloy, L G Horvath, S J Clark, PRIMe consortium

Abstract

Background:Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs). This study assessed whether the level of circulating methylated GSTP1 (mGSTP1) in plasma DNA is associated with chemotherapy response and overall survival (OS).Methods:Plasma samples were collected prospectively from a Phase I exploratory cohort of 75 men with castrate-resistant PC (CRPC) and a Phase II independent validation cohort (n=51). mGSTP1 levels in free DNA were measured using a sensitive methylation-specific PCR assay.Results:The Phase I cohort identified that detectable baseline mGSTP1 DNA was associated with poorer OS (HR, 4.2 95% CI 2.1-8.2; P<0.0001). A decrease in mGSTP1 DNA levels after cycle 1 was associated with a PSA response (P=0.008). In the Phase II cohort, baseline mGSTP1 DNA was a stronger predictor of OS than PSA change after 3 months (P=0.02). Undetectable plasma mGSTP1 after one cycle of chemotherapy was associated with PSA response (P=0.007).Conclusions:We identified plasma mGSTP1 DNA as a potential prognostic marker in men with CRPC as well as a potential surrogate therapeutic efficacy marker for chemotherapy and corroborated these findings in an independent Phase II cohort. Prospective Phase III assessment of mGSTP1 levels in plasma DNA is now warranted.British Journal of Cancer advance online publication, 21 August 2014; doi:10.1038/bjc.2014.463 www.bjcancer.com.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 1%
Unknown 70 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 18%
Student > Master 12 17%
Student > Ph. D. Student 12 17%
Student > Bachelor 8 11%
Student > Doctoral Student 6 8%
Other 9 13%
Unknown 11 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 18 25%
Medicine and Dentistry 18 25%
Agricultural and Biological Sciences 9 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Engineering 2 3%
Other 6 8%
Unknown 16 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2014.
All research outputs
#20,234,388
of 22,760,687 outputs
Outputs from British Journal of Cancer
#10,027
of 10,410 outputs
Outputs of similar age
#197,844
of 235,897 outputs
Outputs of similar age from British Journal of Cancer
#109
of 121 outputs
Altmetric has tracked 22,760,687 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,410 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,897 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.